文献速递系统性红斑狼疮其他结缔组织病

系统性红斑狼疮相关癫痫持续状态的长期结局:一项观察性研究与系统综述

Long-term outcome of status epilepticus-related to systemic lupus erythematosus: An observational study and a systematic review.
PubMed 文献 · Semin Arthritis Rheum · 2023-08-10

该观察性研究汇总了单中心8例及系统综述识别的32例系统性红斑狼疮相关癫痫持续状态(SE-SLE)患者,共40例,分析电临床特征、影像学及病因与长期结局的关系。大多数SE-SLE进展为难治性癫痫持续状态,需积极免疫治疗;癫痫无发作率60.0%,中位停止时间14天;1年死亡率12.5%、复发率25.0%、后续癫痫37.5%、功能结局差55.0%、认知障碍47.5%。停止SE-SLE发作时间延长与长期结局不良相关。

要点

  • SE-SLE临床表型异质,可从先兆持续状态到昏迷;惊厥性SE-SLE见于整体狼疮活动性高及额颞区皮质和皮质下病灶负荷增加的患者。
  • 多数SE-SLE进展为难治性癫痫持续状态,对多种抗癫痫药物和静脉麻醉药抵抗,需积极免疫治疗以终止活动期。
  • 癫痫无发作率60.0%,积极治疗后中位停止SE-SLE发作时间为14天;停止时间延长与长期结局不良相关。

核心结论

  • SE-SLE诊断准确性需更好理解其病因发病机制和临床表现谱;及时启动免疫治疗可改善SE-SLE结局,但最佳治疗策略尚未确定。
  • 识别区分不同形式SE-SLE的新型生物标志物并靶向细胞炎症反应,将有助于制定特异性SE-SLE治疗指南并预防不良结局。

研究设计与样本

  • 观察性研究汇总单中心三级医院8例及系统综述识别的32例SE-SLE患者,共40例,聚焦电临床特征、影像学及SE-SLE潜在病因与长期结局的相关性。

主要发现

  • SE-SLE临床表型异质,范围从先兆持续状态到昏迷。
  • 惊厥性SE-SLE发生于整体狼疮疾病活动性增高及皮质和皮质下脑病灶负荷增加的患者,病灶多定位于额叶和颞叶区域。
  • 无特定神经影像或实验室异常可早期诊断SE-SLE,其中17.5%的病例病因不明。
  • 多数SE-SLE病例进展为难治性SE-SLE,对多种抗癫痫药物和静脉麻醉药抵抗,需积极免疫治疗以使SE-SLE活动期缓解。
  • 60.0%患者达到癫痫无发作,积极治疗后中位停止SE-SLE癫痫活动时间为14天。

临床怎么用

  • 原文结论指出及时启动免疫治疗可改善SE-SLE结局,但最佳治疗策略尚未确定。
  • 原文结论指出识别新型生物标志物以区分不同形式SE-SLE并靶向细胞炎症反应,将有助于制定特异性SE-SLE治疗指南并预防不良结局。

局限性

  • 原文指出SE-SLE诊断准确性需更好理解其病因发病机制和临床表现谱。
  • 原文指出最佳治疗策略尚未确定。
  • 原文指出需识别新型生物标志物以区分不同形式SE-SLE并靶向细胞炎症反应,以帮助制定特异性SE-SLE治疗指南并预防不良结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Status epilepticus-related to systemic lupus erythematosus (SE-SLE) is in general attributed to fulminate neuropsychiatric lupus disease activity, yet the long-term outcome of SE-SLE is not well recognized. This is an observational study of 40 SE-SLE patients pooled from 8 cases at a single tertiary care hospital, and 32 SE-SLE patients identified on a systematic review, with focus on electro-clinical characteristics, imaging studies and the underlying etiology of SE-SLE in correlation with long-term outcome. RESULTS: Clinical phenotypes of SE-SLE were heterogeneous, ranging from patients with aura continua to patients in coma. Convulsive SE-SLE occurred among patients with heightened global lupus disease activity and increased cortical and subcortical brain lesion burden localized mostly in the frontal and temporal regions. There were no specific neuroimaging or laboratory abnormalities that allowed early SE-SLE diagnosis where a cluster of cases were of unclear etiology (17.5%). Most SE-SLE cases evolved to refractory SE-SLE with resistance to multiple anti-seizure medications and intravenous anesthetics requiring aggressive immune therapy that led to resolution of SE-SLE active phase. Seizure freedom occurred in 60.0% of patients and the median time to cessation of SE-SLE seizure activity after aggressive therapy was 14 days. Poor long-term outcomes were apparent in SE-SLE patients with one-year mortality (12.5%), recurrent SE-SLE (25.0%), subsequent epilepsy (37.5.1%), poor functional outcome (55.0%) and cognitive impairment (47.5%). A prolonged time to cessation of SE-SLE seizure activity was associated with unfavorable long-term outcome. CONCLUSIONS: Diagnostic accuracy of SE-SLE requires better understanding of the etio-pathogenesis and the spectrum of clinical presentations of SE-SLE. Prompt initiation of immune therapy improve SE-SLE outcome, yet optimal therapeutic strategies remain to be determined. Identifying novel biomarkers that distinguish between different forms of SE-SLE and target cellular inflammatory response will help with specific SE-SLE treatment guidelines and prevent poor outcome.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Mikdashi J, Krumholz A. Long-term outcome of status epilepticus-related to systemic lupus erythematosus: An observational study and a systematic review. Semin Arthritis Rheum. 2023. PMID: 37595509. doi:10.1016/j.semarthrit.2023.152250

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。